CHU Clermont-Ferrand
Clermont-Ferrand, 63003, France
NCT Number: NCT02618720
To assess the effects of a combined antimicrobial prophylaxis using oral ornidazole (the day before surgery) and intravenous cephalosporin (before surgical incision) with that of intravenous cephalosporin alone (standard of care) in combination with oral placebo on the incidence of SSI within 30 days after elective colorectal surgery.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Clermont-Ferrand, 63003, France
Surgical site infection (SSI) is a major cause of nosocomial infection in surgical patients, with the highest rates being reported (ranging from 15% to 30%) in colorectal surgery. SSI is an independent predictor of postoperative mortality and is associated with longer hospital stay, a 5-fold likelihood of postoperative readmission and a 2- to 3-fold increase in costs of care. Given the high prevalence and financial burden associated with SSI, American and European guidelines have been issued providing evidenced-based recommendations for the prevention of postoperative SSI. However, the prevalence of SSI remains high despite adherence to these guidelines and the application of evidence-based preventive measures.
Risk factors for SSI, whether modifiable or not, are mainly related to the patient condition (including age, severe comorbidity, diabetes, nutritional status, steroid use, smoking, and immunosuppression) and/or the surgical procedure (especially the surgical duration and skin disinfection). The prevention of SSI consists of several individual measures, and antibiotic prophylaxis covering aerobic and anaerobic bacteria is highly recommended in patients scheduled to elective colorectal resection, with French and European guidelines recommending the administration of intravenous cephalosporin within 30 minutes before surgical incision.
Recent data from retrospective studies and two meta-analyses of clinical trials provided compelling arguments that oral antibiotic administration before surgery in addition to conventional intravenous prophylaxis may be useful in further reducing by almost 75% the incidence of SSI (relative risk 0.55 [CI95%: 0.41 to 0.74]) after elective colorectal cancer surgery.
However, most of these studies have limitations precluding extrapolation of data into routine care, especially:
Investigators hypothesized that oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 30 days after surgery
The primary end point of the trial is the occurrence of any SSI within 30 days after surgery. SSI will be classified as superficial, deep and/or organ-space infection according to validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC).
Time frame: 30 days after surgery
Incidence of individual types of SSI (superficial incision infection, deep incision infection and organ-space infection) according to the group of treatment, 30 days after surgery
Time frame: 30 days after surgery
Using the Dindo and Clavien classification
Time frame: 30 days after surgery
Time frame: 30 days after surgery
Including hospital stay of patients who are readmitted after surgery
Time frame: 30 days after surgery
Time frame: 90 days after surgery
Time frame: 30 days after surgery
Time frame: 30 days after surgery
Number of Postoperative syndrome of systemic inflammatory responses, in each group
Time frame: 30 days after surgery
Number of Sepsis, in each group
Time frame: 30 days after surgery
Number of Septic shocks, in each group
Time frame: 30 days after surgery
Number of arrhythmias, in each group
Time frame: 30 days after surgery
Number of myocardial infarctions, in each group
Time frame: 30 days after surgery
Number of acute cardiac failures, in each group
Time frame: 30 days after surgery
Number of pneumonias, in each group
Time frame: 30 days after surgery
Number of postoperative reventilations (intubation and/or non-invasive mechanical ventilation), in each group
Time frame: 30 days after surgery
Number of Renal dysfunctions in each group. Defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) classification
Time frame: 30 days after surgery
Comparaison of time to initiation of adjuvant chemotherapy between the 2 groups
Time frame: 30 days after surgery
Number of hospital readmissions, in each group
Time frame: 30 days after surgery
Number of Unexpected admissions to intensive care unit, in each group
Time frame: 30 days after surgery
University Hospital, Clermont-Ferrand
Other
Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery: A Double-blinded Multicenter Prospective Randomized Controlled Trial
Acronym: COMBINE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02756273
Elective Colorectal Surgery
Rouen, France
View Trial DetailsNCT04411199
Abdominal Surgery, Colon Surgery
Augusta, Georgia, United States
View Trial DetailsNCT04366440
Infections, Pathologic Processes
St. Petersburg, Florida, United States
View Trial DetailsNCT06108791
Infections, Pathologic Processes
Asyut, Egypt
View Trial Details